Pomalidomide-PEG6-CO2H is primarily utilized in the development of antibody-drug conjugates (ADCs) and targeted drug delivery systems. Its structure, featuring a pomalidomide moiety linked to a PEG6 spacer and a carboxylic acid group, allows for efficient conjugation with antibodies or other targeting molecules. This enables precise delivery of the drug to specific cells, such as cancer cells, while minimizing off-target effects. The PEG6 spacer enhances solubility and stability, improving the pharmacokinetics of the conjugate. Additionally, the carboxylic acid group facilitates covalent attachment to amines or other reactive groups on the targeting molecule, ensuring a stable linkage. This compound is particularly valuable in oncology research for designing therapies that selectively target and destroy malignant cells.